Free tool
FAERS Monitor: Sulfamylon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016763 or its brand name (Sulfamylon, Mafenide Acetate). Reports on generic versions are filed under their own applications.
Reports
31
Serious
25
81% of reports
Hospitalization
11
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4
- pyrexia4
- sepsis4
- wound infection3
- agitation2
- anxiety2
- clostridium difficile colitis2
- dry skin2
- erythema2
- fatigue2
- gait disturbance2
- hypotension2
- medication error2
- multiple organ dysfunction syndrome2
- nausea2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,128 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wound infectionSignal | 3 | 185.9 | 63.4 | 382 |
| clostridium difficile colitis | 2 | 128.0 | 33.5 | 141 |
| multiple organ dysfunction syndrome | 2 | 47.9 | 12.5 | 51 |
| medication error | 2 | 24.4 | 6.4 | 25 |
| sepsisSignal | 4 | 24.3 | 9.7 | 68 |
| agitation | 2 | 18.5 | 4.8 | 18 |
| dry skin | 2 | 10.2 | 2.7 | 9 |
| pyrexiaSignal | 4 | 7.8 | 3.1 | 18 |
| gait disturbance | 2 | 7.1 | 1.9 | 5 |
| hypotension | 2 | 6.8 | 1.8 | 5 |
| erythema | 2 | 6.6 | 1.7 | 5 |
| anxiety | 2 | 4.8 | 1.2 | 3 |
| drug ineffective | 4 | 2.1 | 0.8 | 1 |
| fatigue | 2 | 1.7 | 0.5 | 0 |
| nausea | 2 | 1.7 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.